These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 32358910)

  • 1. Omalizumab in children and adolescents with chronic spontaneous urticaria: Case series and review of the literature.
    Passanisi S; Arasi S; Caminiti L; Crisafulli G; Salzano G; Pajno GB
    Dermatol Ther; 2020 Jul; 33(4):e13489. PubMed ID: 32358910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion.
    Vestergaard C; Toubi E; Maurer M; Triggiani M; Ballmer-Weber B; Marsland A; Ferrer M; Knulst A; Giménez-Arnau A
    Eur J Dermatol; 2017 Feb; 27(1):10-19. PubMed ID: 27882879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of as-needed antihistamines in chronic spontaneous urticaria patients under omalizumab treatment.
    Türk M; Yılmaz İ; Nazik Bahçecioğlu S; Can P; Ertaş R; Kartal D; Çınar SL; Kocatürk E
    Dermatol Ther; 2021 Jan; 34(1):e14543. PubMed ID: 33190334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
    Metz M; Ohanyan T; Church MK; Maurer M
    J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
    Ghazanfar MN; Holm JG; Thomsen SF
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of chronic inducible urticaria according to the guidelines: A prospective controlled study.
    Kocatürk E; Can PK; Akbas PE; Copur M; Degirmentepe EN; Kızıltac K; Singer R
    J Dermatol Sci; 2017 Jul; 87(1):60-69. PubMed ID: 28314658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between chronic spontaneous urticaria and chronic induced urticaria on the efficacy of omalizumab treatment: A systematic review and meta-analysis.
    He ZH; Qiu SC; Huang ZW; Zhang GQ; An QQ; Qu F; Wang N
    Dermatol Ther; 2022 Dec; 35(12):e15928. PubMed ID: 36222320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: A multi-center retrospective case series.
    Ari A; Levy Y; Segal N; Maoz-Segal R; Benor S; Broides A; Horev A; Epstein-Rigbi N; Agmon-Levin N; Marcus N
    Pediatr Dermatol; 2020 Nov; 37(6):1051-1054. PubMed ID: 32951239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old.
    Agache I; Akdis CA; Akdis M; Brockow K; Chivato T; Del Giacco S; Eiwegger T; Eyerich K; Giménez-Arnau A; Gutermuth J; Guttman-Yassky E; Maurer M; Ogg G; Ong PY; O'Mahony L; Schwarze J; Warner A; Werfel T; Palomares O; Jutel M
    Allergy; 2022 Jan; 77(1):17-38. PubMed ID: 34324716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An observational study on the efficacy of single injection of omalizumab in the treatment of chronic spontaneous urticaria.
    Lal Vijayalal S; Arora S; Dabas R; Janney MS; Jankal Basavarajappa S; Das NM
    Dermatol Ther; 2020 Nov; 33(6):e14397. PubMed ID: 33040395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of clinical factors as possible predictors of response to omalizumab and relapse after treatment discontinuation in chronic spontaneous urticaria.
    Foti C; Romita P; Ambrogio F; Fanelli M; Panebianco R; Vena GA; Cassano N; Ragusa M; Giuffrida R; Papaianni V; Borgia F; Cannavò SP; Guarneri F
    Dermatol Ther; 2022 Feb; 35(2):e15248. PubMed ID: 34877757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of the updosing of second-generation non-sedating H1 antihistamines in children with chronic spontaneous urticaria.
    Sarti L; Barni S; Giovannini M; Liccioli G; Novembre E; Mori F
    Pediatr Allergy Immunol; 2021 Jan; 32(1):153-160. PubMed ID: 32745323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omalizumab in chronic urticaria.
    Metz M; Maurer M
    Curr Opin Allergy Clin Immunol; 2012 Aug; 12(4):406-11. PubMed ID: 22766620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Chronic Spontaneous Urticaria in Routine Clinical Practice Following the EAACI/GA(2)LEN/EDF/WAO Guidelines.
    Marín-Cabañas I; Berbegal-de Gracia L; de León-Marrero F; Hispán P; Silvestre JF
    Actas Dermosifiliogr; 2017 May; 108(4):346-353. PubMed ID: 28219634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
    Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
    Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience.
    Acar A; Gerceker Turk B; Ertam Sagduyu I; Ceylan C; Ozturk G; Unal I
    Cutan Ocul Toxicol; 2020 Sep; 39(3):249-253. PubMed ID: 32597235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-reported hair loss in patients with chronic spontaneous urticaria treated with omalizumab: an under-reported, transient side effect?
    Konstantinou GN; Chioti AG; Daniilidis M
    Eur Ann Allergy Clin Immunol; 2016 Sep; 48(5):205-7. PubMed ID: 27608479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective treatment of different phenotypes of chronic urticaria with omalizumab: Case reports and review of literature.
    Kasperska-Zajac A; Jarząb J; Żerdzińska A; Bąk K; Grzanka A
    Int J Immunopathol Pharmacol; 2016 Jun; 29(2):320-8. PubMed ID: 26729404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omalizumab therapy for chronic spontaneous urticaria: the Israeli experience.
    Rottem M; Segal R; Kivity S; Shamshines L; Graif Y; Shalit M; Kessel A; Panasoff J; Cohen S; Toubi E; Agmon-Levin N
    Isr Med Assoc J; 2014 Aug; 16(8):487-90. PubMed ID: 25269339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the Efficacy and Recurrence of Omalizumab Use in the Treatment of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria.
    ; Yu R; Qian W; Zheng Q; Xiong J; Chen S; Chen A; Chen J; Fang S; Huang K; Cai T
    Int Arch Allergy Immunol; 2023; 184(7):643-655. PubMed ID: 36996780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.